Clinical Trial

Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, efficacy, and immunogenicity of different dose levels (low, medium, and high) of Chlamydia messenger ribonucleic acid (mRNA) Vaccine candidate in adult participants aged 18 to 29 years. This study will consist of 3 Sentinel Cohorts and a Main Cohort, with the Sentinel Cohorts assessing the safety of the different dose levels in a stepwise manner. All participants will be followed up to 12 months after the last study intervention administration. Thus, the expected duration of the participant's involvement will be 18 months.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-17; most recent amendment 2026-04-02.
Status change: Active, Not Recruiting → Recruiting 2026-04-02
Status change: Recruiting → Active, Not Recruiting 2025-07-18
Status change: Not Yet Recruiting → Recruiting 2025-03-28
Trial Details
NCT Number NCT06891417
Lead Sponsor Sanofi
Conditions Chlamydia Trachomatis Immunization
Enrollment 1,560 participants
Start Date 2025-03-27
Primary Completion 2028-01-03 (estimated)
Study Completion 2028-01-03 (estimated)
Updated on ClinicalTrials.gov 2026-04-08